Document is current
Any future updates will be listed below
-
Authors
Alcon, Clara https://orcid.org/0000-0003-3243-9440
Kovatcheva, Marta https://orcid.org/0000-0002-2536-1043
Morales-Sánchez, Paula https://orcid.org/0000-0002-9563-668X
López-Polo, Vanessa https://orcid.org/0000-0001-6165-2510
Torres, Teresa
Puig, Susana
Lu, Albert
Samitier, Josep https://orcid.org/0000-0002-1140-3679
Enrich, Carlos
Serrano, Manuel https://orcid.org/0000-0001-7177-9312
Montero, Joan https://orcid.org/0000-0002-9192-4836
- License Information
-
More Information
Article History
Received: 14 June 2024
Revised: 7 November 2024
Accepted: 12 November 2024
First Online: 3 December 2024
Competing interests
: JM is co-inventor of dynamic BH3 profiling (patented by Dana-Faber Cancer Institute, also BH3 profiling used in this study) and has received royalties. JM is a paid consultant for PEP-THERAPY, was a paid consultant for Oncoheroes Biosciences and Vivid Biosciences, is an unpaid board member for The Society for Functional Precision Medicine, and he is currently collaborating with AstraZeneca. MS is shareholder of Altos Labs, Inc., Senolytic Therapeutics, Inc., Life Biosciences, Inc., and Rejuveron Senescence Therapeutics, AG. No potential conflicts were disclosed by the other authors.
: Patient samples were retrospectively included in our study with prior fully informed patient consent and approval from the Local Ethical Committee (HCB/2019/0995 V.4 11/12/2019). The study was conducted in accordance with the principles of the Declaration of Helsinki.
